Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Total Debt

Last Annual Value

186.35K

3-Year CAGR

11%

5-Year CAGR

-10%

10-Year CAGR

33%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Total Debt

NTRB · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
186.35K
-8.3%6.7%33.4% 
94.14M
0.6%73.2%N/A
0.00
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
2.71M
-16.4%-13.6%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
14.74M
-11.0%-6.8%-18.8%
732.07K
-10.7%-14.6%N/A
13.40M
22.6%31.1%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
8.98M
-30.3%-18.2%40.5%
IMA logo
ImageneBio Inc
NASDAQ:IMA
9.99M
-2.4%7.4%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
684.00K
-20.0%-7.2%N/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15